A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

ABSTRACT:

Lessons learned

Pazopanib shows a modest efficacy in metastatic alveolar soft part sarcoma.Clinical outcomes were comparable to those in previous studies using antiangiogenic drugs.Further prospective studies evaluating the benefit of pazopanib in alveolar soft part sarcoma with a larger sample are warranted to validate results.

Background

Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignant tumor characterized by an unbalanced translocation, t(X;17)(p11.2;q25), which leads to the fusion of ASPSCR1 to the TFE3 transcription factor. Because this results in the upregulation of angiogenesis-related transcripts, antiangiogenic drugs have been used in ASPS patients.

Methods

This open-label, single-arm, multicenter, investigator-initiated phase II

SUBMITTER: Kim M 

PROVIDER: S-EPMC6324645 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature